Identification of Disulfiram as a Potential Therapeutic for RB1 -proficient and -deficient Triple Negative Breast Cancer

Identification of Disulfiram as a Potential Therapeutic for RB1 -proficient and -deficient Triple Negative Breast Cancer

Show other versions (1)

Triple negative breast cancer (TNBC) represents an aggressive subtype for which only chemotherapy is available. The RB1 tumour suppressor is frequently lost in human breast cancer, primarily in TNBC. Loss of RB1 deregulates the cell cycle and is thought to affect BC response to endocrine, radiation,...

Full description

Bibliographic Details
Main Author:	Robinson, Tyler
Other Authors:	Zacksenhaus, Eldad
Language:	en_ca
Published:	2013
Subjects:	triple negative breast cancer chemotherapy retinoblastoma protein disulfiram role of RB1 during chemotherapy IQGAP1 disulfiram treats triple negative breast cancer 0306 0307 0379
Online Access:	http://hdl.handle.net/1807/65435

Similar Items

Identification of Disulfiram as a Potential Therapeutic for RB1 -proficient and -deficient Triple Negative Breast Cancer
by: Robinson, Tyler
Published: (2013)

New chemotherapy options for triple-negative breast cancer (review of literature)
by: M A Sekundova, et al.
Published: (2014-03-01)

Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer
by: Yajing Huang, et al.
Published: (2020-10-01)

Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review
by: Jessa Gilda P. Pandy, et al.
Published: (2019-11-01)

Clinical Initial Response of Neoadjuvant Chemotheraphy in Triple Negative, HER-2, and Luminal Types of Breast Cancer in Denpasar (A Preliminary Study)
by: Kristianto Yuli Yarso, et al.
Published: (2012-01-01)

Clinical Initial Response of Neoadjuvant Chemotheraphy in Triple Negative, HER-2, and Luminal Types of Breast Cancer in Denpasar (A Preliminary Study)
by: Kristianto Yuli Yarso, et al.
Published: (2012-01-01)

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
by: Javier Pérez-Pena, et al.
Published: (2019-12-01)

Silencing of PGK1 Promotes Sensitivity to Paclitaxel Treatment by Upregulating XAF1-Mediated Apoptosis in Triple-Negative Breast Cancer
by: Shanshan Sun, et al.
Published: (2021-03-01)

The Evolving Role of Disulfiram in Radiobiology and the Treatment of Breast Cancer
by: Wang R, et al.
Published: (2020-10-01)

The efficacy of neoadjuvant chemotherapy and survival in older patients with stages II to III triple-negative breast cancer
by: Olga O Gordeeva, et al.
Published: (2019-09-01)

Results of combination treatment for triple-negative breast cancer
by: M. A. Sekundova, et al.
Published: (2014-07-01)

Targeted Liposomal Chemotherapies to Treat Triple-Negative Breast Cancer
by: Yingnan Si, et al.
Published: (2021-07-01)

Orbital Metastasis from Triple-Negative Breast Cancer: Case Report and Literature Review
by: Kamal El Bakraoui, et al.
Published: (2020-09-01)

Comparison of outcomes between metaplastic and triple-negative breast cancer patients
by: Praveen Polamraju, et al.
Published: (2020-02-01)

BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study
by: Yoshimasa Kosaka, et al.
Published: (2020-02-01)

NUP98 – a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer
by: Paul B. Mullan, et al.
Published: (2019-04-01)

CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy
by: Bray Denard, et al.
Published: (2018-08-01)

Immunotherapeutic interventions of Triple Negative Breast Cancer
by: Zehuan Li, et al.
Published: (2018-05-01)

Transcriptomic analyses identify key differentially expressed genes and clinical outcomes between triple-negative and non-triple-negative breast cancer
by: Chen B, et al.
Published: (2018-12-01)

A clinicopathologic study of triple negative breast cancer
by: Vandana L Gaopande, et al.
Published: (2015-01-01)

Soybean lecithin stabilizes disulfiram nanosuspensions with a high drug-loading content: remarkably improved antitumor efficacy
by: Haowen Li, et al.
Published: (2020-01-01)

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
by: Omarini C, et al.
Published: (2018-01-01)

The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
by: Olga Caramelo, et al.
Published: (2019-03-01)

The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis
by: Xingfa Huo, et al.
Published: (2021-01-01)

Disulfiram reaction
by: Banjac Nada, et al.
Published: (2019-01-01)

Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)
by: Arlindo R. Ferreira, et al.
Published: (2018-01-01)

Overview of Antabuse® (Disulfiram) in Radiation and Cancer Biology
by: Jia Y, et al.
Published: (2021-05-01)

Cytotoxic Activity of Sphingosine-1-Phosphate against Human Triple-negative/ Basal-like Breast Cancer
Published: (2016)

Bioactive nanotherapeutic trends to combat triple negative breast cancer
by: Pallabita Chowdhury, et al.
Published: (2021-10-01)

Enhanced Paclitaxel Efficacy to Suppress Triple-Negative Breast Cancer Progression Using Metronomic Chemotherapy with a Controlled Release System of Electrospun Poly-<span style="font-variant: small-caps">d</span>-<span style="font-variant: small-caps">l</span>-Lactide-Co-Glycolide (PLGA) Nanofibers
by: Ming-Yi Hsu, et al.
Published: (2021-07-01)

Disulfiram-like reaction with ornidazole
by: Sharma V, et al.
Published: (2009-01-01)

Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy
by: Gizem Oner, et al.
Published: (2021-09-01)

Relation Between CD8+T Lymphocyte Infiltration and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer
by: KONG Tiandong, et al.
Published: (2021-05-01)

Cowpea Mosaic Virus Immunotherapy Combined with Cyclophosphamide Reduces Breast Cancer Tumor Burden and Inhibits Lung Metastasis
by: Hui Cai, et al.
Published: (2019-08-01)

Triple-negative breast cancer outcomes: Does AJCC 8th staging improve chemotherapy decision-making
by: Chen-Lu Lian, et al.
Published: (2021-10-01)

Moringa Oleifera Seed Extract Concomitantly Supplemented with Chemotherapy Worsens Tumor Progression in Mice with Triple Negative Breast Cancer and Obesity
by: Elizabeth R. M. Zunica, et al.
Published: (2021-08-01)

PIM-1 kinase: a potential biomarker of triple-negative breast cancer
by: Chen J, et al.
Published: (2019-08-01)

CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer
by: Zi-Ming Zhao, et al.
Published: (2019-01-01)

Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents
by: Vinodh Kannappan, et al.
Published: (2021-09-01)

SGLT1 is required for the survival of triple‐negative breast cancer cells via potentiation of EGFR activity
by: Huiquan Liu, et al.
Published: (2019-09-01)

Cannot write session to /tmp/vufind_sessions/sess_n0fjuqs6u96g9pqjl6j8f9jngq